Welcome to LookChem.com Sign In|Join Free

CAS

  • or

116089-38-4

Post Buying Request

116089-38-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

116089-38-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 116089-38-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,0,8 and 9 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 116089-38:
(8*1)+(7*1)+(6*6)+(5*0)+(4*8)+(3*9)+(2*3)+(1*8)=124
124 % 10 = 4
So 116089-38-4 is a valid CAS Registry Number.

116089-38-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-benzylsulfanylbenzenethiol

1.2 Other means of identification

Product number -
Other names o-benzylthiobenzolthiol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:116089-38-4 SDS

116089-38-4Relevant articles and documents

Uebergangsmetallkomplexe mit Schwefelliganden XXXIV. II(CO)2>-Fragmente als Templatzentren und Schutzgruppen: Synthese makrozyklischer Thioether und Monoalkylierung von Dithiolen; Roentgenstrukturanalyse von Dibenzo-18-krone-S6, einem planar

Sellmann, Dieter,Frank, Peter,Knoch, Falk

, p. 345 - 356 (1988)

Using metal carbonyl fragments as templates, the directed, bridging alkylation of ligating dithiolates yields macrocyclic polythioethers.Treatment of cis-2- (1) with S(C2H4Br)2, in THF at room temperature, gives Fe(CO)-(dptt

Method of treatment for benign prostatic hyperplasia

-

, (2008/06/13)

Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5α-reductase inhibitor, e.g. a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an α1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 116089-38-4